Nordson (NDSN) Q3 2025 Earnings Call Transcript

Image source: The Motley Fool.

Date

Aug. 21, 2025 at 8:30 a.m. ET

Call participants

President and Chief Executive Officer — Sundaram Nagarajan

Executive Vice President and Chief Financial Officer — Daniel Hopgood

Need a quote from a Motley Fool analyst? Email pr@fool.com

Takeaways

Total sales--Nordson(NASDAQ:NDSN) reported $742 million for the third quarter of fiscal 2025 (period ended July 31, 2025), up 12% from $662 million in the prior-year third quarter, with 8% from the Atrion acquisition, 2% organic growth, and 2% positive currency impact.

Advanced Technology Solutions (ATS) segment sales-- $171 million, up 17%, with 15% organic sales growth led by electronics dispense and measurement product lines.

Medical and Fluid Solutions segment sales-- $219 million, up 32%, with $52 million from Atrion; organic sales (excluding held-for-sale contract manufacturing business) grew 4%.

Industrial Precision Solutions (IPS) segment sales-- $351 million, up 1%, with a 2% organic decline offset by a 3% favorable currency impact; strength in precision agriculture and nonwoven systems, offset by continued weakness in polymer processing.

Gross profit-- $407 million, representing 55% of sales, consistent with the prior year.

Adjusted operating profit-- Increased 15% after adjusting for acquisition-related and divestiture charges.

EBITDA-- $239 million or 32% of sales, up 15% year over year; ATS segment EBITDA rose 35% to $42 million (24% of sales).

Adjusted EPS-- $2.73, up 13% from $2.41, and $0.08 above the quarterly guidance midpoint; statutory EPS was $2.22.

Free cash flow-- Record $226 million, equal to 180% of net income.

Leverage ratio-- Reduced to 2.2x EBITDA from 2.5x at year start, with net debt of about $2 billion and $148 million cash on hand.

Share repurchases-- Over $70 million in shares repurchased during the quarter; year-to-date total of $212 million; new board authorization raised repurchase capacity by $500 million, providing approximately $800 million in total authorization outstanding.

Annualized restructuring savings-- Targeted actions in underperforming businesses expected to yield over $15 million in annual savings by 2026.

Divestiture-- Sale of the medical contract manufacturing business on track to close in the fourth quarter, resulting in a $12.2 million charge, primarily from goodwill write-down and minor restructuring costs.

Capital allocation-- $44 million in dividends paid and $12 million spent on capital investment to drive organic growth.

2025 full-year guidance-- Management expects sales to finish slightly below the midpoint of full-year guidance for fiscal 2025 (inclusive of the planned divestiture); full-year EPS is anticipated "slightly better than the midpoint" due to operational execution and sustained margins.

Summary

The Atrion acquisition contributed 8% to total sales growth in the third quarter of fiscal 2025, with management confirming it was accretive to earnings per share one year ahead of schedule. The ATS segment delivered its second consecutive quarter of double-digit organic sales growth, with management citing demand across electronics and semiconductor end-markets and ongoing volatility in order timing. Free cash flow conversion reached record levels, as operational improvements in working capital drove a 180% free cash flow conversion rate of net income, enabling significant capital deployment toward debt reduction, share repurchases, and continued investment. Management reiterated a strategic focus on divesting low-margin contract manufacturing assets, targeting higher-value proprietary medical components post-divestiture, while also implementing restructuring measures in underperforming product lines to yield over $15 million in annual cost savings by fiscal 2026. The board's new share repurchase authorization of $500 million, increasing capacity to approximately $800 million, underscores confidence in the balance sheet and provides flexibility for balanced capital allocation as M&A opportunities remain under disciplined review.

Sundaram Nagarajan said, "we are at the beginning of a multiyear growth here" in ATS, confirming momentum as the segment exits a cyclical downturn.

Adjusted tax rate was 19%, maintained at the low end of guidance after excluding a discrete goodwill write-down tied to the contract manufacturing exit.

Despite some weakness and "muted" order entry for large plastic processing and industrial coating systems, management stated these businesses have "hit the trough" and order activity is showing signs of recovery.

Recurring revenue streams remained stable and substantial in IPS, helping offset cyclical softness in system orders.

Daniel Hopgood stated, "we're not seeing direct evidence And when I say direct evidence, we're not getting requests from customers to accelerate orders. Or to accelerate activity. So you know, there's no direct evidence, at least from our activity, of pulling things forward that you know, I think the harder thing to put your arms around is is there any inherent pull ahead in any of the capital cycles. But certainly, we're not seeing direct evidence or request from customers to pull anything forward." in semiconductor-related ATS orders, though lumpiness remains inherent to the segment.

Several proprietary product launches were called out, including the Spectrum S2 for electronics underfill and the Pharmalog zero clamp, underscoring the company's innovation-led growth framework.

Industry glossary

Atrion: Acquired medical technology company specializing in proprietary infusion fluid delivery and cardiovascular solutions, integrated into Nordson's portfolio.

NBS Next: Nordson's internal growth and operational excellence framework, focused on commercial execution, customer proximity, and product innovation.

CDMO: Acronym for Contract Development and Manufacturing Organization; Nordson's medical contract manufacturing business categorized for divestiture.

Spectrum S2: Nordson's electronics industry system for underfill application, cited as an industry standard and a key driver for ATS sector market share gains.

Full Conference Call Transcript

Naga will discuss third quarter highlights. He will then turn the call over to Dan to review sales and earnings performance for the total company and the three business segments. Dan will also discuss the balance sheet and cash flow. Naga will then share a high-level commentary about our enterprise performance and provide an update on the fiscal 2025 full-year guidance. We will then be happy to take your questions. With that, I'll turn to slide four and turn the call over to Naga.

Sundaram Nagarajan: Good morning, everyone. Thank you for joining Nordson's fiscal 2025 third quarter conference call. In the quarter, the Nordson team responded effectively to dynamic demand conditions in the key markets. This generated sales of $742 million, which is above the midpoint of our guidance with solid contribution from both organic and inorganic growth. The advanced technology solutions segment was a big contributor to this performance, delivering a second consecutive quarter of double-digit organic sales growth. Operational excellence drove strong profit performance, increasing adjusted earnings per share by 13% and EBITDA by 15% compared to the prior year. The third quarter was the final full quarter of Atrion's first year post-acquisition.

As you will recall, we closed the Atrion acquisition on August 21, 2024, expanding Nordson's medical portfolio into proprietary medical infusion fluid delivery and niche cardiovascular solutions. In the quarter, our employees again exceeded expectations and contributed to both sales and earnings results. This is the result of commercial scale that Nordson has brought to the business as well as the positive market acceptance of the product portfolio. Their operational performance reflects solid execution of the integration plan, as well as the ongoing deployment of NBS Next. I would also like to highlight our free cash flow of $226 million and cash flow conversion of 180% of net income during the quarter.

This represents record quarterly free cash flow and was driven by a focus on sustainable working capital improvements. We use this cash to reduce debt, repurchase shares, and return dividends to the shareholders, all the while continuing to invest in the company. I will speak more about the enterprise performance in a few moments, but first, I'll turn the call over to Dan to provide a detailed perspective on our financial results for the quarter.

Daniel Hopgood: Thank you, Naga, and good morning, everyone. On slide number five, you'll see third quarter fiscal 2025 sales of $742 million were up 12% from the prior year third quarter sales of $662 million. As Naga mentioned, the Atrion acquisition continues to perform above expectations and contributed 8% to our growth in the quarter. Total organic sales increased 2% and were up 3% if you exclude the medical contract manufacturing business that is now treated as held for sale. Our organic performance includes contributions from both our advanced technology and medical fluid solutions segments. During the quarter, we also had a positive year-over-year currency impact of 2% in the quarter, adding to that performance.

Gross profit in the third quarter was $407 million, a healthy and consistent 55% of sales. Our SG&A leverage improved year-over-year, leading to a 15% improvement in operating profit adjusted for acquisition-related costs and amortization and charges associated with the exit of our medical contract manufacturing business. EBITDA was $239 million or 32% of sales. This represents a 15% increase in EBITDA dollars and a 70 basis point improvement over the prior year third quarter. EBITDA growth continues to benefit from strong incrementals in our ATS segment as well as contributions from the Atrion acquisition. It's worth noting that in a very dynamic trade environment, our margin performance remains consistent and is a continued strength of the company.

Looking at non-operating expenses, non-net interest expense was $26 million, an increase of $8 million versus the prior year, driven by higher year-over-year debt levels tied to the Atrion acquisition. Other expenses increased $3 million, primarily reflecting higher foreign exchange transactional losses compared to the prior year. And our tax expense on a US GAAP basis was $33 million. This represents an elevated effective tax rate of 21% in the quarter and reflects discrete nondeductible charges, namely the write-down of allocated goodwill associated with the pending exit of the medical contract manufacturing business.

Excluding this discrete item, our effective tax rate on an adjusted basis was 19% and remains in line with the low end of our guidance range for fiscal 2025. Net income in the quarter totaled $126 million, $2.22 per share. Excluding acquisition-related costs and amortization and charges associated with the exit of the medical contract manufacturing business, adjusted earnings per share totaled $2.73 per share, 8¢ above the midpoint of our quarterly guidance, and a 13% increase from the prior year adjusted earnings per share of $2.41. This improvement in year-over-year earnings reflects the strong operational execution on higher sales, as well as accretive contribution from the Atrion acquisition.

Now let's turn to slides six through eight to review the third quarter 2025 segment performance. Industrial precision solutions sales of $351 million increased 1% compared to the prior year third quarter. While improving sequentially from the second quarter, organic sales decreased 2% compared to the prior year, offset by a 3% favorable currency impact. Broad-based growth across the segment, in particular, double-digit growth in precision agriculture and nonwoven systems, was offset by continued weakness in our polymer processing product lines, where we continue to see lower end market systems demand versus February 2024. EBITDA for the segment was $130 million in the quarter, or 37% of sales, essentially flat to the prior year.

If you turn to slide seven, you'll see medical and fluid solution sales of $219 million increased 32% compared to the prior year's third quarter. Growth was driven by the acquired Atrion business, which delivered $52 million in revenue in the quarter. Excluding the pending divestiture, organic sales increased 4% in the quarter, led by improvements in our medical fluid components and fluid solutions product lines. Importantly, sales in our interventional solutions business continued to improve sequentially from the second quarter as expected and were flat compared to the prior year as we continue to move past the recent destocking trends.

EBITDA for medical and fluid solutions was $83 million or 38% of sales, which was an increase of 34% from prior year EBITDA of $62 million. The increase was driven by strong conversion on Atrion sales and SG&A leverage in the core businesses. Turning to slide eight, you'll see advanced technology solution sales of $171 million, a 17% increase compared to the prior year third quarter. The 15% organic sales increase was driven by double-digit growth in electronics dispense product lines, driven by demand across Asia Pacific, as well as growth in our optical sensors and our measurement and controls businesses. This was partially offset by weakness in X-ray inspection system sales during the quarter.

Third quarter EBITDA was $42 million or 24% of sales, which represents an increase of 35% compared to the prior year third quarter EBITDA of $31 million or 21% of sales. The improvement in EBITDA margin was driven by strong operational execution on sales growth, representing a 42% conversion rate on incremental sales volume. Finally, turning to the balance sheet and cash flow on page nine. At the end of the third quarter, we had cash on hand of $148 million and net debt was about $2 billion.

Importantly, we continue to sequentially improve leverage quarter after quarter, driven by both EBITDA growth and a reduction in net debt, improving our leverage ratio from 2.5 times at the start of the year to 2.2 times the end of the third quarter. Our free cash flow generation reached a record $226 million during the quarter, resulting in a 180% conversion rate on net income for the quarter and a year-to-date cash flow conversion rate of 140%. The strong cash conversion was driven by operational improvements in working capital, an area of emphasis in this dynamic environment.

In the quarter and in line with our balanced capital deployment strategy, we reduced net debt by over $100 million, repurchased over $70 million in shares, paid $44 million in dividends to our shareholders, and spent $12 million on capital investments to continue driving organic growth. In summary, we had a strong operational quarter. Our team delivered on their commitments despite ongoing uncertainty in geopolitical and trade policies. While market conditions remain mixed for some of our businesses, we're well-positioned to capitalize on profitable growth opportunities, and our operational execution continues to be a strength for the company. With that, let's turn to slide 10, and I'll turn the call back to Naga.

Sundaram Nagarajan: Thanks, Dan. I'm very proud of the Nordson team and how they have been able to deliver for our customers in this dynamic environment. As highlighted on slide 10, our strong growth portfolio, high recurring revenues, diversified niche end markets, close-to-the-customer model, proprietary differentiated products, and NBS Next framework positions us well for long-term growth. Turning to Slide 11. I'd like to take a few moments to talk about what we're seeing in the end markets as we enter our fiscal 2025 fourth quarter. Starting with our industrial precision solutions segment, we continue to see sustaining investments in packaging and nonwoven end markets.

Precision agriculture demand is improving in Europe and South America, given the strengthening demand for increasing yields and quality in these regional markets. Throughout the year, there has been weakness in our polymer processing systems, and we believe this business has hit its trough. Industrial Coating Solutions Systems are sequentially improving, but cold material product lines for automotive systems continue to be weak. Through it all, aftermarket parts remain a stable part of the IPS revenue portfolio, mitigating sales weakness and supporting margins. Overall, we expect the IPS segment to improve sequentially and return to normal growth rates as selected markets stabilize. In medical, our core business is returning to growth.

Throughout the year, our medical fluid component product lines have returned to high single-digit growth. The interventional solutions portfolio is normalizing after several quarters of destocking, and we expect this business to return to normal organic growth in fiscal 2026. The demand drivers fueling this end market, such as the aging population and shift toward noninvasive surgeries, have not changed, and our medical team has a healthy pipeline of customer projects. In ATS, this is our second consecutive quarter of double-digit organic growth. The work that our ATS team did to reposition our product portfolio and regional manufacturing has allowed us to be where our customers need us to be as supply chains shift for electronics assembly.

We're also winning share based on our ability to deliver products in incredibly short lead times. This would not have been possible before we holistically applied NBS Next. In addition to being located close to the customer, our products deliver leading productivity and quality in complex advanced packaging applications of semiconductors used for AI, cloud computing, and more. Our applications are largely at the back end of the semiconductor packaging process, and we are experiencing that demand now. Demand in this business inherently is lumpy, based on the needs and timing of our customers.

Through the cycle, we expect long-term growth drivers will remain attractive while also appreciating that we will start to come up against tougher comparisons starting in the fourth quarter and that the automotive exposure within our electronics portfolio continues to be weak. Regardless of the end market dynamics, we have continuously demonstrated resilience and the ability to deliver solid growth and best-in-class profitability. Our NBS Next growth framework ensures new products are a growing source of organic growth and competitive advantage. I would like to highlight a few of them. The Nordson Spectrum S2 is the industry standard for electronics underfill application. It continues to win share in the market, particularly as customers move into new regions.

Its quality, accuracy, and ease of use make it a trusted resource, and our teams continue to build upon its strong foundation for today's standards. Our industrial coatings business has launched the first of a multiyear platform rollout of new global controls for its power coating systems. This new control system has a plug-and-play feature that would simplify operations and improve ease of use for our customers. Finally, I would like to highlight the new Nordson medical Pharmalog zero clamp, which is a great example of the continued innovation in fluid components. This proprietary clamp ensures consistent sealing, eliminating leaks with any fittings on the market, and improving assembly time for biopharma customers. We also remain focused on operational execution.

As I mentioned earlier, we are very pleased with the integration of the Atrion acquisition, which contributed to the adjusted earnings per share during the quarter. That is a year earlier than originally expected. We knew there were opportunities for operational efficiency when we acquired this business, and the team's holistic implementation of NBS Next has accelerated those benefits. In businesses where we are experiencing weaker customer demand, we have implemented targeted restructuring to adjust cost structure. These actions have been substantially completed and are expected to provide ongoing annual benefits of over $15 million by 2026. Our growth framework ensures we remain intentional about where we focus within our product portfolio.

As we noted last quarter, we plan to divest the contract manufacturing portion of our medical device product line. That transaction is expected to close in the fiscal fourth quarter. Exiting these product lines will increase our focus on higher-value proprietary medical components, including devices from the recent Atrion acquisition. Finally, as Dan mentioned earlier, a strong balance sheet allowed us to take advantage of the dynamic market conditions in the third quarter and accelerate share repurchases. Year to date, we have bought back $212 million in shares. I'm also pleased to share that our board of directors has approved a new authorization to repurchase $500 million in shares, bringing our total remaining authorization to approximately $800 million.

In the quarter, we also reduced our leverage to 2.2 times EBITDA, well within our long-term target. This demonstrates our ongoing commitment to a balanced capital deployment strategy. Turning now to outlook on Slide 13. Benefiting from the strong third quarter, we now expect to be slightly below the midpoint of our full-year sales guidance, inclusive of the pending divestiture of our medical contract manufacturing business. On earnings, we expect to be slightly better than the midpoint of our full-year guidance based upon our strong operational execution and ability to maintain margins in this dynamic environment. As always, I want to thank our customers and shareholders for your continued support.

In particular, I want to thank our Nordson employees for being passionate about meeting the needs of our customers. Your efforts show. With that, we will pause and take your questions.

Operator: We will now begin the question and answer session. If you would like to ask a question, please raise your hand now. If you have dialed into today's call, please press 9 to raise your hand and 6 to unmute. Please standby while we compile the Q&A roster. Your first question from the line of Jeffrey D. Hammond with KeyBanc Capital Markets. Your line is open. Please go ahead.

Jeffrey Hammond: Yeah. Good morning. Can you hear me? Morning, Jeff. Good morning, Jeff. Okay. Great. So I just wanted to get a better feel for what you're seeing from an order momentum standpoint. You know, across the businesses. Particularly, I guess, ATS where you know, you've spilled some momentum, and now you're talking about a little bit tougher comps. And then you know, medical as we kinda get through the you know, the destocking and maybe just some color around you know, the backlog down sequentially. Is that you know, that a function of timing or some you know, some air pockets in the in the order book?

Sundaram Nagarajan: We'll split it two ways here, Jeff. Let Dan first take the question around backlog initially. And then I'll give you sort of color of the end markets in a broader way. Dan, you wanna get started?

Daniel Hopgood: Yeah. So know, I wouldn't overreact to the slight reduction in our backlog quarter to quarter. I think some of that is really a factor of or strong shipments during the third quarter. What I would say in general, Jeff, is we're seeing know, good stability in order intake, across our businesses. Yes. Particularly about medical, I would say, you know, we're seeing good ongoing activity in our medical businesses. ATS, again, you know, as I think Naga mentioned in some of the opening comments, tends to be a little more lumpy. But we are seeing overall, what I was what I would call good stable demand in all three of our businesses.

I wouldn't overreact to the to the back decline. I think that's really a function of timing of shipments. And what I would say in general is we're seeing good stability underlying our order patterns.

Jeffrey Hammond: Yep. Okay. Let me let me give you a broad color of where we are seeing things and how it is showing up in our order entry, Jeff. Overall, as we look in to finish the end of the year, based on our current order entry trends and backlog, we are well positioned to deliver on the guidance. Which is slightly below our midpoint for the revenue. That's sort of an overarching comment that I wanna share with you. The second, if you go segment by segment, if you look at IPS, we see pretty strong and pretty steady order entry in packaging nonwoven end markets.

Our precision ag demand is very strong, And remember, this is an European based business. We are market leaders in Europe and in South America. Both markets recovering nicely for this business. Order entry is looking pretty good there. PPS, which is our plastics business, still remains weak, but it has hit its trough. You know? It is bottoming out. In our industrial coatings business, which is sort of the two system businesses that have been weak, for the segment. Throughout the year. The powder system side is pretty strong. But our automotive exposure here through cold materials is remains weak. So IPS overall, other than the two system businesses, in very good shape.

If you think about MFS, the medical segment, it is returning to growth. We have now had a couple of quarters of our medical fluid component business high single digit growth. In our interventional component business, what you find is the destocking has normalized. And we expect to return to growth here. This quarter, it was flat. And without you know, if you exclude our pending divestiture, this business would have had a 4% organic growth. And our fluid solutions division is doing fairly well. It is steady. This is a little bit related. To electronic momentum in this business. In terms of ATS, continued strong order entry backlog, well positioned at we go into the fourth quarter. Look.

This business we have always shared with you. It is a lumpy business. But the momentum for this business in terms of both semiconductor packaging investments high reliability electronics, PCBA electronic equipment. Pretty strong and solid. And if you think about another new secular trend that is benefiting the company, particularly in ATS, is the redesign of supply chain by some of our customers. So semiconductor on track, electronic peep PCBA, high reliability ones are doing well. And then third, you have, we have benefits coming from redesign of supply chain as people redesign to derisk to account for tariffs.

So overall, I've you know, I'll I'll close with what I told you at the beginning, which is backlog order entry in a good place for us to deliver on the revenue guidance that we shared with you today.

Jeffrey Hammond: Okay. And then just to follow-up on ATS. I mean, I understand, you know, maybe some lumpiness timing in the March. Yep. And you know, and then and then maybe a tougher comp, but maybe still an easy comp into April. But you know, it still seems like we're coming out of a multiyear down cycle, and I just wanna make sure you know, I'm reading that right.

Sundaram Nagarajan: Yeah. You are reading that right. We are coming out of a multiyear, and we're you know? But the cycle has begun. Right? We have now had three or four quarters of growth. You know? Okay. One back and down. The best way to think about it is, look. Look at the nine months of 8%. Okay? First quarter was down. Second quarter, pretty nicely up. Third quarter, really up. So if you start to think about that, yes. You know, you're reading it right. We you know, we are at the beginning of a multiyear growth here. The growth prospects for ATS are intact. And we don't we don't see that changing in the near term.

Jeffrey Hammond: Okay. Perfect. Thanks, guys. Appreciate it.

Sundaram Nagarajan: Sure.

Operator: Your next question comes from the line of Michael Pesendorfer with Baird Equity Research. Your line is open. Please go ahead.

Michael Pesendorfer: Good morning, everyone. Pez on for Mike. So I just want to follow-up on Jeff's question on ATS here. You know, we've heard some rumblings on pull forward in the semiconductor complex, and I just wanna make sure that I'm reading your comments correctly. You're talking about an improvement in the cycle and things starting to take off. So help me understand your assumptions sequentially into the fourth quarter as it relates to ATS? And maybe help us with a little bit of color across dispense and T and I across acoustic X-ray and three d optical.

Daniel Hopgood: So, yeah, if you just go back to some of those comments, you know, well, I'll I'll start with the Paul had comment. We're we're not seeing direct evidence And when I say direct evidence, we're not getting requests from customers to accelerate orders. Or to accelerate activity. So you know, there's no direct evidence, at least from our activity, of pulling things forward that you know, I think the harder thing to put your arms around is there any inherent pull ahead in any of the capital cycles. But certainly, we're not seeing direct evidence or request from customers to pull anything forward. Yeah.

I think if I if I look across the businesses, you know, we're seeing pretty broad based demand in our electronics dispense products. We're seeing we've been seeing good solid demand from our acoustic and optical products throughout the year. And if I look at our pipeline in our we really don't see that changing. Again, not as bad. We'll go back to Naga's point. There tends to be some lumpiness and could be some lumpiness order to quarter with some of these capital cycles. But from an underlying demand standpoint, we see good stable demand in these markets.

Sundaram Nagarajan: In a couple of things, Dan, sorry to interrupt. But if I could add, you know, one of the things to remember is in this business also, what matters is new product. You know, what matters is customers' demands, customers' new applications, and Nordson being really strong in delivering on solving customers' new problems. So we have number of new products that are getting launched in this business that are meeting the needs of you know, ever more complex chips that our customers are making. And so, you know, we feel really good about this business and feel really good about where we are headed in the cycle.

But you know, continue to remind you quarter to quarter that is going to be back and forth of orders and what the you know? What we wanna do is make sure we take care of the customer when they want this, where they want this. And that is super important in this business. If you look back and think about how Nordson wins, Nordson wins with technology. New product's essential. But at the same time, we have added operational excellence as a core capability for the company, and that is allowing us to win share, when it is available. And third, is agility. Our teams are incredibly agile.

And so what you see in the third quarter is a great evidence of agility of the entire Nordson team, but particularly the ATS team. Where we have moved things around to deliver on what the customer wanted, when they want it, where they want it. Right? And I think in that way, I would tell you, I feel really good about where we are. And I feel really good about where we are headed.

Michael Pesendorfer: That's super helpful color. I appreciate that, Dan and Naga. Switching gears a little bit. Obviously, the balance sheet, in great shape. The increase in the share repurchase authorization. Can you maybe comment a little bit on how you see the M and A funnel today? Where you're spending your time and the level of opportunity? Should we be reading the share repurchase authorization as the M and A funnel maybe being a little bit tougher or is that more of just a broad based comment on how you're approaching capital allocation?

Sundaram Nagarajan: Yeah. I the way to think about Pez is that you know, we have you know, in our investor day, we committed to a balanced capital allocation strategy. So what you see play out throughout this year is a very balanced approach. You know, we did see an opportunity in the quarter with where the market is at and where our valuation at. It made sense for us to continue to buy back share, and that's what we've done. You know? Year to date, we have repurchased about $212 million in shares. And the new authorization gives us more flexibility as we go into the rest of the year. Commenting on the M and A our pipeline is healthy.

Pipeline is healthy. We continue to work opportunities. But look. We're gonna be really disciplined around what strategic assets we would acquire as well as what we would pay for them and financially being disciplined about them. So no change in our approach or posture to acquisitions, but acquisition is something we don't control. Right? Things come to market when they come to market. And if it makes sense for us, we certainly do. You know, I would take a moment to just think about Atrion. Right? It is about a year since we have acquired Atrion. This is a commercial and operational success story for the company. Right?

And if you stop and think about where we are at on Atrion, we are now EPS accretive a year ahead of schedule. Right? And so our, you know, posture on acquisition remains the same. It is a balanced approach. Over a period of three or four years, what you're going to find the company is have balanced organic and balanced acquisition. So the new authorization shouldn't be read into any difference in our approach to acquisitions.

Michael Pesendorfer: Understood. Thank you all.

Operator: As a reminder, if you would like to ask a question, please raise your hand now. The raise hand button can be found in the center toolbar at the bottom of your screen. Your next question comes from the line of Edward Magi with BNP Paribas. Your line is open. Please go ahead.

Edward Magi: Hey. Good morning, guys. This is Ed on for Andrew. For taking my question. Good morning.

Sundaram Nagarajan: Morning.

Edward Magi: The latest sales guidance for slightly below the midpoint seems to be slightly better than your prior guidance of saying low end, but that commentary from Q1, Q2 came from when tariffs have been maybe weighing a little bit more on sentiment. And after the solid Q3, wondering if you guys could have perhaps improved the outlook a little bit more with today's tariff situation looking a little bit better than it did during those prior guides.

Daniel Hopgood: Yeah. So I appreciate the question. Well, maybe I'll just start with a bit of a recap. Right? So, you know, look, We had a slow start to the year as you'll recall. With our first quarter sales being softer than expected. And at that point, we guided that we would be on the lower end of our sales revenue guidance. And so, you know, two quarters later, in particular, after finishing out a strong third quarter, I think you're correct to, you know, take away that we're we're improving our outlook slightly. Not saying that we'll just be slightly below the midpoint, and that also incorporates closing on the sale of our CDMO business during the fourth quarter.

So that, you know, taking that into account, you're correct in assuming that there's a slight improvement in our sales outlook largely driven by the performance that we saw in Q3. And at this point, I would say we're very comfortable holding our outlook for the fourth quarter.

Sundaram Nagarajan: Right. And I think, you know, just as a reminder, think about the economic environment that we are living in. It is still a very dynamic environment with a number of uncertainties still out there. Sure. The tariff situation, we continue to gain clarity every day, but it's still uncertain sort of what we see in our customers' behavior. So the way we are thinking about it is, look. Dynamic environment, not in fully participating in market momentum where it exists, and delivering one quarter at a time. And that has served us well and will continue to serve us well in this environment.

Edward Magi: Yeah. Very helpful. Thanks, guys. And then, an unrelated follow-up. With regard to the divestiture charges, are you able to unpack went into that $12 million? And then is there anything else we can expect to see in the fourth quarter assuming that closes on track?

Daniel Hopgood: Yeah. The charge, roughly $12.2 million is essentially writing the business to estimated fair value less cost to sell. And in the actual close of the deal in the fourth quarter. There's also some small restructuring charges included in that to kind of wrap up and exit a couple of small pieces of the business. And so I would think of that as a one-time charge. Certainly, the actual closing will be and the value will be dependent on final working capital and truing up a few items. But I wouldn't expect any material change to that $12.2 million. And as we actually closed the deal in the fourth quarter.

Edward Magi: Helpful. Thanks, guys.

Operator: Your next question comes from the line of Walter S. Liptak with Seaport Research Partners. Your line is open. Please go ahead. Walter, just a reminder to unmute yourself.

Walter Liptak: Okay, sorry. Good morning, everyone. Can you hear me?

Sundaram Nagarajan: Yep.

Walter Liptak: Good morning, Paul. Okay. Great. Good morning. So the in the ATS segment, there was some good discussion, and, Naga, you brought up, new product development. And, I wonder if we could try and tie something together. You know, AI is a fairly powerful new technology. Yeah. And you have a lot of exposure on the consumer side. You know, not just automotive, but a whole bunch of consumer products that have electronics. Yes. Are you seeing your consumer products companies start to do redesign where they can you know, make smart products that leverage the AI tech?

Sundaram Nagarajan: Yeah. You know, look. AI is still evolving for many of our customers. And in terms of our own view of AI is certainly very bullish in terms of what AI brings, in terms of value to the customers as well as ourselves. Yes. We do see people wanting to figure out how to use AI and how to create value. The way we think about value is really, for AI is you know, three things. One, it starts with customer value creation. We have couple of ideas. I would say at this stage, it is more ideas that we are working on.

That will allow our customers to use our own products in a much more effective, much more productive ways, and particularly, X-ray business. we have new software subscription services in our Very early stages, very early stages, but super exciting as to how our teams are beginning to use AI to create value. In terms of AI for our own customers using them and how they will use our products, very early stages. Hope that answers your question, Walter.

Walter Liptak: Okay. Yeah. It does. Thank you. And just switching gears to IPS. Know, I was wondering if you could talk a little bit about the photo order cycle. You know, there's been, like, this pause going on because of all of the you know, the headwinds that we all know about are you are you seeing any improvement in know, kind of, you know, maybe a lifting of the pause? Thanks.

Sundaram Nagarajan: Are you talking, Walter, just a clarification? You're talking about people's sentiments around ordering or placing orders for systems. Is that what you're talking about?

Walter Liptak: Yeah. For, for larger systems Okay. It just seems like generally there's Sure. A reluctance to put capital to work just because of the tariffs specifically and not knowing Yeah. You know, what the rules are gonna be. Yes. I you know, I would look if you look at our IPS business, if you think about the magnitude of the spend, vast majority of our IPS businesses, Right? Around 60, 70% of the business, we seem to be in a fairly good place. In terms of orders coming in. We're you know, if you think about packaging, nonwovens, product assembly, many of our businesses, which have still system sales, 50% system sales, there we don't see major pauses.

We seem to be doing okay. And that but if you look at our plastic processing business, our industrial coatings business, both we do see pauses. By our customers Order entry order entry is muted for systems, But if you look at our customer pipeline, they're very robust. Nobody in our customer pipeline is saying, look. I don't want that anymore. It is that people are not placing orders. So larger system orders, you're you're right. We are seeing people delaying their own you know, order placement.

Walter Liptak: Okay. Still some caution, I guess, is And just to add maybe one more piece of color, I would say, in plastics in particular, you know, we have seen, you know, we have seen some rebuilding of that pipeline certainly from earlier in the year. So we are seeing activity back up or rebound, I think, Naga made the comment. We feel that business has hit the trough.

Sundaram Nagarajan: Yep.

Daniel Hopgood: We are seeing that in our backlog. Certainly not at levels that we've seen in prior years yet. But we are seeing recovery in order activity Although we are also seeing some of our pipeline activity get pushed out.

Sundaram Nagarajan: Yeah. And the other thing to remember about IPS, look. This is a business some significant recurring revenue. Right? More like $50.50. So if you think about system parts, a significant part of the, IPS segment in fairly good shape. It is the large system businesses that are have this order issue but you also have these businesses now starting to get to the bottom of the trough, not getting any worse. Other than the automotive small automotive exposure in ICS, that is still weak.

But all in all, you take all of that together, we still feel pretty good about where we are sitting here today in terms of order entry, and in terms of backlog to be able to meet what we were sharing as in revenue guidance.

Walter Liptak: Thank you, guys.

Operator: Your next question comes from the line of Brad Hewitt with Wolfe Research. Your line is open. Please go ahead.

Brad Hewitt: Hi. Good morning. Can you hear me, guys?

Sundaram Nagarajan: Yes. Yes.

Brad Hewitt: Great. Sorry about that. So it seems like your outlook is for organic sales to be flat to slightly down year over year in Q4? I think that would imply a little bit of a deceleration on a three-year stack basis. I know ATS has a tough comp in Q4, but maybe any additional color on what's driving that expected deceleration in Q4 would be helpful.

Daniel Hopgood: Yeah. So it to your point, I think if you look at a couple of our businesses, and particular, even our systems businesses, we have some tough year-end comps, plastics being one of them as an example. And so sequentially, know, if you kinda peel back our guidance, we are seeing a modest uptick Q3 to Q4 also continuing to build sales momentum. From a year-over-year standpoint. I think Q4 is a tougher comp for some of our systems businesses. And so I think that's what you're seeing in kind of the year-over-year growth rate. But not really certainly not a deceleration from where we've been running.

We're you know, if you peel back our guidance, it would indicate a modest uptick in the fourth quarter from what we've seen in Q3. From a year-over-year standpoint, it's a little bit more muted but that's largely driven by some of the systems demand and deliveries that we had in the fourth quarter last year.

Brad Hewitt: Okay. That's helpful. And then as we think about ATS margins, is that segment sort of at a normalized run rate in the 24% to 25% zone sort of in the absence of a more material step up in systems demand? As we think about FY 'twenty six, would you expect ATS incremental margins to be in line with the total company level or maybe even a little better?

Sundaram Nagarajan: Well, yeah, look. This is a business we have repositioned the business during the downturn at the last downturn. And so what you're experiencing right now is a pretty strong incremental performance, which is a little bit better than the rest of the company. At the current revenue run rate, you know, the 24% seems reasonable, but I wouldn't go any further than that. Because remember, this is a business that depends on new products and continuous investment in new products. So here, the SG&A load is far greater than everywhere else. Our investments in new products are more like 14, 15% of revenue. Which is very different from our other businesses.

So I wouldn't want you to get too far ahead of our here. But the 24% EBITDA, 24, 25 seems reasonable.

Brad Hewitt: Great. Thank you.

Operator: As a final reminder, if you would like to ask a question, please raise your hand now. The raise hand button can be found in the center toolbar at the bottom of your screen. If you have joined via Zoom mobile, tap the more three dots option in the lower right corner of the meeting controls and select raise hand. If you have dialed into today's call, please press 9 to raise your hand and 6 to unmute. There are no further questions at this time. I will now turn the call back to Naga for closing remarks.

Sundaram Nagarajan: Thank you for your time and attention on today's call. We have several upcoming investor events where our team would be happy to meet with you. Including the Jefferies Industrial Conference in New York on September 4, the Morgan Stanley Annual Laguna Conference on September 10, and an upcoming virtual roadshow with Loop Capital on October 13. Nordson is well positioned in this dynamic environment. Our close-to-the-customer model, proprietary and niche technology, diversified geographic, and end market exposure, high level of recurring revenue, and a strong balance sheet are among many attributes that make us a quality compounder. Have a great day. This concludes today's call. Thank you for attending. You may now disconnect.

Where to invest $1,000 right now

When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor’s total average return is 1,052%* — a market-crushing outperformance compared to 183% for the S&P 500.

They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor.

See the stocks »

*Stock Advisor returns as of August 18, 2025

This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. Parts of this article were created using Large Language Models (LLMs) based on The Motley Fool's insights and investing approach. It has been reviewed by our AI quality control systems. Since LLMs cannot (currently) own stocks, it has no positions in any of the stocks mentioned. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability.

The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.